Biogen (BIIB) Liabilities and Shareholders Equity (2009 - 2026)

Biogen's Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $32.1 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 13.26% year-over-year to $32.1 billion; the TTM figure through Jun 2026 stood at $120.2 billion (up 6.65% YoY), while the FY2025 annual figure was $29.4 billion, up 4.96% from the prior year.
• Liabilities and Shareholders Equity for Q2 2026 stood at $32.1 billion, up from $29.5 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $32.1 billion in Q2 2026, with the low at $23.6 billion in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $27.4 billion (2023), against an average of $27.2 billion.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity fell 1.01% in 2022, then gained 13.43% in 2023.
• Biogen's Liabilities and Shareholders Equity stood at $24.6 billion in 2022, then advanced by 9.33% to $26.8 billion in 2023, then increased by 4.49% to $28.0 billion in 2024, then increased by 4.96% to $29.4 billion in 2025, then increased by 8.99% to $32.1 billion in 2026.
• Business Quant data shows BIIB's Liabilities and Shareholders Equity at $32.1 billion in Q2 2026, $29.5 billion in Q1 2026, and $29.4 billion in Q4 2025.